RNS Number : 4533I
Shield Therapeutics PLC
14 December 2020

**Shield Therapeutics plc**
("Shield" or the "Group" or the "Company")

**Director/PDMR shareholding**

**London, UK, 14 December 2020:** Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Tim Watts, Chief Executive Officer, has acquired 100,000 Ordinary Shares in the Company on 11 December 2020 for consideration of £0.6975 per Ordinary Share. Following the transaction, Mr Watts holds 548,700 shares.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

| | | |
|---|---|---|
| **1** | **Details of the person discharging managerial responsibilities/person closely associated** | |
| a) | Name | Tim Watts |
| **2** | **Reason for the notification** | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/ Amendment | Initial Notification |
| **3** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | |
| a) | Name | Shield Therapeutics plc |
| b) | LEI | 213800G74QWY15FC3W71 |
| **4** | **Details of the transaction(s): section to be repeated for (i) each type of instrument;<br>(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | |

| | | |
|---|---|---|
| a) | Description of the financial instrument, type of instrument<br><br>Identification code | Ordinary shares of 1.5p each in the capital of the Company<br><br>ISIN of Ordinary Shares: GB00BYV81293 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares |
| c) | Price(s) and volume(s) | £0.6975 per Ordinary Share<br>Volumes: 100,000 |
| d) | Aggregated information<br><br>-Aggregated volume<br><br>-Price | <br><br>100,000<br><br>£69,750.00 |
| e) | Date of the transaction | 11 December 2020 |
| f) | Place of the transaction | London Stock Exchange, AIM Market |

**For further information please contact:**


**Shield Therapeutics plc** www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500
Karen Chandler Smith, Investor Relations

***Nominated Adviser and Joint Broker***
**Peel Hunt LLP**
James Steel/Dr Christopher Golden +44 (0)20 7418 8900

***Joint Broker***
**finnCap Ltd** +44 (0)20 7220 0500
Geoff Nash/Matt Radley/Alice Lane

***Financial PR & IR Advisor***
**Walbrook PR** +44 (0)20 7933 8780

or shield@walbrookpr.com
Paul McManus/Lianne Cawthorne +44 (0)7980 541 893 / +44 (0)7584 391 303

**About Shield Therapeutics plc**

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDFLFFBLLLFBQ